Roche says SMA drug meets trial goal

Roche said on Monday its drug risdiplam helped people with type 2 or 3 spinal muscular atrophy improve their motor function, as the Swiss drugmaker presses ahead with a medicine it sees rivaling Biogen's Spinraza and Novartis's Zolgensma.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.